Pharmacists in Los Fresnos, TX Accepting Medicare

7 Pharmacists found. Showing 1 - 7

Michael Matthew Nino Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1004 W Ocean Blvd, Los Fresnos, TX 78566 Phone: 956-233-1822    Fax: 956-233-1798

Lisa Christina Krawczynski, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Walmart Supercenter, 1004 W. Ocean Blvd., Los Fresnos, TX 78566 Phone: 956-233-1822    Fax: 956-233-1798

Anthony Gonzalez Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1004 W Ocean Blvd, Los Fresnos, TX 78566 Phone: 956-233-1822    Fax: 956-233-1798

Dr. Amy Jong Alvis, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 27991 Buena Vista Blvd, Los Fresnos, TX 78566 Phone: 956-504-7279    Fax: 756-504-7284

Dr. Jose Elias Gonzalez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 W Ocean Blvd Ste A1, Los Fresnos, TX 78566 Phone: 956-233-3400

Robert Valentin Salinas, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 810 W Ocean Blvd, Los Fresnos, TX 78566 Phone: 956-233-3400    Fax: 956-233-3402

Amairani Valentina Benavides Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1004 W Ocean Blvd, Los Fresnos, TX 78566 Phone: 956-233-1822

News Archive

Esperion, Cleveland Clinic collaborate to research new HDL therapies for cardiovascular disease

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease.

Study investigates mental health consequences of COVID-19 geriatric care in nursing homes

No matter one's age, race, gender, socioeconomic status or political party, COVID-19 has impacted everyone at some level. That impact has been especially palpable for the approximately 1.3 million elderly Americans who reside in the country's 15,600 nursing homes.

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

TheraDoc's patient safety surveillance system helps hospitals manage their H1N1 responses effectively

As the battle against the H1N1 influenza outbreak continues, hospitals are on the front lines, charged with identifying, treating, monitoring, and reporting flu cases—as well as preventing their spread to other patients and hospital personnel. To facilitate this arduous task, a growing number of U.S. hospitals are using a patient safety surveillance system developed by TheraDoc that helps them more effectively coordinate their responses to this serious public health threat.

Australian researchers to discover proteins that cause multiple sclerosis

Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.

Read more Medical News

› Verified 6 days ago